Nor-LSD
| Clinical data | |
|---|---|
| Other names | norLSD; N,N-Diethyl-6-norlysergamide; N-Desmethyllysergic acid diethylamide; N-Desmethyl-LSD; Norlysergic acid diethylamide; N-Demethyl-LSD; 9,10-Didehydro-N,N-diethylergoline-8β-carboxamide; H-LAD; 6-Nor-LSD |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.623 |
| Chemical and physical data | |
| Formula | C19H23N3O |
| Molar mass | 309.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nor-LSD, or norLSD, also known as N,N-diethyl-6-norlysergamide or as N-desmethyllysergic acid diethylamide (N-desmethyl-LSD), is a serotonin receptor modulator and putative psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the methyl group at the 6 position of the ergoline ring system has been removed.